Risks to the 340B Drug Pricing Program / Reply

Knox and Sarpatwari respond to comments from Daifotis on their article regarding the risks to the 340B drug pricing program. Pharmaceutical manufacturers have unilaterally adopted a range of policies concerning the delivery of 340B discounted drugs to contract pharmacies, from requiring that certain...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2022-09, Vol.328 (11), p.1109
Main Authors: Daifotis, Anastasia G, Knox, Ryan P, Sarpatwari, Ameet
Format: Article
Language:English
Subjects:
Constraining
Drug delivery
Drugs
Pricing
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Knox and Sarpatwari respond to comments from Daifotis on their article regarding the risks to the 340B drug pricing program. Pharmaceutical manufacturers have unilaterally adopted a range of policies concerning the delivery of 340B discounted drugs to contract pharmacies, from requiring that certain covered entities submit insurance claims data for 340B drugs dispensed at these locations to limiting the number of contract pharmacies a covered entity can engage. They believe that it is accurate to label the former policy, which imposes a limiting condition, as a restriction.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2022.12753